Cycle Pharmaceuticals announced the launch of HARLIKU, the first and only FDA-approved treatment for reducing urinary homogentisic acid (HGA) in adult patients with alkaptonuria (AKU). 1 AKU, also ...

Antibiotic innovation, rising female UTI cases, and diagnostic advances are key drivers shaping the future of the UTI market. CA, UNITED STATES, July 15, 2025 /EINPresswire.com/ -- Urinary tract ...

"I was a very healthy person; I ate well, worked out often and took care of my husband. Then all of a sudden, I couldn't do anything for myself." ...

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

A lembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya (pivmecillinam ...

Pivmecillinam proved highly effective in treating uUTIs, with trial reanalysis supporting its FDA approval after decades of ...

Doctors and scientists are hopeful that the non-antibiotic treatment could ultimately help millions of patients ...

Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated ...

TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, is available to customers ...

Three lots of a drug designed to treat various urinary tract infections have been recalled because the white round tablets might have black spots from microbial contamination. The spotting of ...